The Na+/K+-ATPase is the Achilles Heel of multi-drug-resistant cancer cells
- 1 September 2009
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 282 (1) , 30-34
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Na+/K+-ATPase α subunits as new targets in anticancer therapyExpert Opinion on Therapeutic Targets, 2008
- Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activityMolecular Cancer Therapeutics, 2008
- Comparison of Cellular Metabolic Responses of 18 F-FDG According to the Effect of β -Irradiation in p53 Wild and Deleted Cell LinesCancer Biotherapy and Radiopharmaceuticals, 2007
- p53 dependent and independent sensitivity to oxaliplatin of colon cancer cellsBiochemical Pharmacology, 2007
- UNBS1450: A new hemi‐synthetic cardenolide with promising anti‐cancer activityDrug Development Research, 2007
- Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)Biochemical Pharmacology, 2007
- The α1 subunit of the sodium pump could represent a novel target to combat non‐small cell lung cancersThe Journal of Pathology, 2007
- Cardenolide-Induced Lysosomal Membrane Permeabilization Demonstrates Therapeutic Benefits in Experimental Human Non-Small Cell Lung CancersNeoplasia, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- A study of human small‐cell lung carcinoma (hsclc) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistanceInternational Journal of Cancer, 1990